Indian political will to be put to test as Cipla seeks Isentress voluntary licence
This article was originally published in Scrip
Pressure is continuing to mount on India to demonstrate the political will to invoke compulsory licensing provisions for 'unaffordable' life-saving medicines, after another domestic firm, Cipla, said that it is seeking a voluntary licence for a cut-price version of Merck & Co's HIV drug Isentress (raltegravir).
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.